Business
Scientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development
From Dish to Bedside: Tenured Harvard Professor, Started Multiple Biotechs, to Grow Early Stage Pipeline SAN RAFAEL, Calif., Oct. 5, 2020 /PRNewswire/ --
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"From Dish to Bedside: Tenured Harvard Professor, Started Multiple Biotechs, to Grow Early Stage Pipeline\n\n\nSAN RAFAEL, Calif., Oct. 5, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., as Group Vice President, Head of Research and Early Development, effective today. Dr. Eggan brings almost two decades of experience in groundbreaking scientific research in rare neurological disorders. \n\n \n \n \n \n \n \n\n \n\"We are thrilled to welcome Kevin to BioMarin to lead research and early development building upon our decades of research in rare genetic diseases. Throughout his career, Kevin has demonstrated a consistent track record of groundbreaking scientific research. His philosophy of 'Dish to Bedside' illustrates how optimizing basic pre-clinical models can enhance therapeutic candidates and selection of trial participants,\" said Lon Cardon, Ph.D., Chief Scientific Strategy Officer, Senior Vice President at BioMarin. \"Kevin comes to BioMarin at an exciting time as our understanding of genetics and biology serve as the underpinnings of BioMarin's strategic vision to deliver transformational therapies that meaningfully change the course of rare genetic diseases.\"\nDr. Eggan will be responsible for the execution of BioMarin's discovery research programs and will play a critical role in shaping the vision of the company's future research pipeline. He will head BioMarin's Research organization and provide scientific leadership throughout the drug discovery process. Dr. Eggan is charged with further building BioMarin's leadership position in genetic medicines in support of people affected by rare genetic diseases and contributing to the long-term growth of BioMarin through the oversight of an exceptional pipeline of first- or best-in-class therapies. \n\"I am excited to join BioMarin at this point in the company's trajectory and am looking forward to bringing my experience to a diverse and established research organization well-respected among academics and industry alike. I was attracted to the Company's pioneering approach to drug discovery and development and its culture of collaboration and caring. The possibilities for science to change the way we think about disease are plentiful, and BioMarin is an idea...